The related deals between Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. announced April 6 appear to be a win for both sides. [See Deal] They extend and update a highly successful 10-year-old collaboration, essentially tweaking the original agreement’s terms in consideration of each partner’s current needs. [See Deal] At the same time, they recognize that the key product involved, the antipsychotic medication Abilify (aripiprazole), is reaching maturity.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?